Cubist Systematic Strategies LLC boosted its stake in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 1,041.0% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,423 shares of the biopharmaceutical company’s stock after acquiring an additional 3,123 shares during the quarter. Cubist Systematic Strategies LLC’s holdings in Agios Pharmaceuticals were worth $176,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. Spark Investment Management LLC raised its stake in Agios Pharmaceuticals by 139.9% during the second quarter. Spark Investment Management LLC now owns 84,700 shares of the biopharmaceutical company’s stock worth $4,357,000 after acquiring an additional 49,400 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Agios Pharmaceuticals by 8.3% during the first quarter. Geode Capital Management LLC now owns 263,899 shares of the biopharmaceutical company’s stock worth $15,410,000 after purchasing an additional 20,336 shares during the last quarter. Hood River Capital Management LLC grew its holdings in shares of Agios Pharmaceuticals by 2.3% during the second quarter. Hood River Capital Management LLC now owns 118,844 shares of the biopharmaceutical company’s stock worth $6,115,000 after purchasing an additional 2,626 shares during the last quarter. Goldman Sachs Group Inc. grew its holdings in shares of Agios Pharmaceuticals by 4.9% during the second quarter. Goldman Sachs Group Inc. now owns 681,093 shares of the biopharmaceutical company’s stock worth $35,042,000 after purchasing an additional 31,969 shares during the last quarter. Finally, TD Asset Management Inc. grew its holdings in shares of Agios Pharmaceuticals by 4.9% during the second quarter. TD Asset Management Inc. now owns 30,000 shares of the biopharmaceutical company’s stock worth $1,544,000 after purchasing an additional 1,400 shares during the last quarter. Hedge funds and other institutional investors own 93.51% of the company’s stock.

In related news, Director Lewis Clayton Jr. Cantley sold 4,000 shares of the firm’s stock in a transaction dated Wednesday, August 23rd. The stock was sold at an average price of $56.85, for a total value of $227,400.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO David P. Schenkein sold 6,000 shares of the firm’s stock in a transaction dated Wednesday, November 1st. The shares were sold at an average price of $63.85, for a total value of $383,100.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 178,908 shares of company stock worth $12,147,719. 10.55% of the stock is owned by company insiders.

AGIO has been the topic of several research analyst reports. BidaskClub cut Agios Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, August 9th. Royal Bank Of Canada initiated coverage on Agios Pharmaceuticals in a report on Thursday, September 14th. They set an “outperform” rating and a $78.00 target price on the stock. Oppenheimer Holdings, Inc. restated an “outperform” rating and set a $83.00 target price (up previously from $75.00) on shares of Agios Pharmaceuticals in a report on Thursday, August 10th. J P Morgan Chase & Co restated a “buy” rating and set a $76.00 target price on shares of Agios Pharmaceuticals in a report on Monday, September 18th. Finally, SunTrust Banks, Inc. restated a “buy” rating and set a $80.00 target price on shares of Agios Pharmaceuticals in a report on Wednesday, October 4th. Three analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. Agios Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $75.70.

TRADEMARK VIOLATION NOTICE: This news story was published by Watch List News and is the property of of Watch List News. If you are reading this news story on another domain, it was copied illegally and republished in violation of US & international copyright and trademark legislation. The legal version of this news story can be accessed at https://www.watchlistnews.com/agios-pharmaceuticals-inc-agio-holdings-lifted-by-cubist-systematic-strategies-llc/1682281.html.

Agios Pharmaceuticals, Inc. (AGIO) opened at $66.49 on Monday. Agios Pharmaceuticals, Inc. has a 1-year low of $39.24 and a 1-year high of $72.73.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($1.59) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.78) by $0.19. The business had revenue of $11.35 million for the quarter, compared to analysts’ expectations of $10.85 million. Agios Pharmaceuticals had a negative return on equity of 69.64% and a negative net margin of 506.39%. The firm’s quarterly revenue was up 26.4% compared to the same quarter last year. During the same quarter last year, the business earned ($1.63) earnings per share. equities research analysts forecast that Agios Pharmaceuticals, Inc. will post -6.69 EPS for the current fiscal year.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.

Institutional Ownership by Quarter for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.